Open AccessTargeting E3 ubiquitin ligases to sensitize cancer radiation therapy
Author(s) -
Chen Zan,
Xu Wei
Publication year - 2019
Publication title -
precision radiation oncology
Language(s) - English
Resource type - Journals
ISSN - 2398-7324
DOI - 10.1002/pro6.1069
Subject(s) - ubiquitin , ubiquitin ligase , radiation therapy , cancer , cancer research , dna damage , dna repair , cancer cell , signal transduction , inflammation , medicine , biology , bioinformatics , immunology , microbiology and biotechnology , dna , biochemistry , gene
Radiotherapy is an effective treatment for many cancer patients to eliminate malignant cells and increase survival rate. However, cancer cells can develop resistance in response to radiation through activation of signaling pathways that promote cell cycle progression, DNA damage response, cell survival, and inflammation. Various combination therapies are developed to sensitize radiotherapy by targeting key signaling proteins involved in radioresponse. The past decade has seen significant advances in the knowledge of ubiquitin signaling in cancer biology. Developing E3 ubiquitin ligase‐related molecules as novel strategies to cure cancer has become an emerging field. This review briefly discusses the potential of targeting diverse E3 ubiquitin ligases as promising strategies for radiosensitization in cancer.